These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31502417)

  • 1. Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
    Hoover P; Der E; Berthier CC; Arazi A; Lederer JA; James JA; Buyon J; Petri M; Belmont HM; Izmirly P; Wofsy D; Hacohen N; Diamond B; Putterman C; Davidson A
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):233-242. PubMed ID: 31502417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Power of Systems Biology: Insights on Lupus Nephritis from the Accelerating Medicines Partnership.
    Fava A; Raychaudhuri S; Rao DA
    Rheum Dis Clin North Am; 2021 Aug; 47(3):335-350. PubMed ID: 34215367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging public private partnerships to innovate under challenging budget times.
    Portilla LM; Rohrbaugh ML
    Curr Top Med Chem; 2014; 14(3):326-9. PubMed ID: 24283971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 5. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 6. A principled partnership between academic medicine and industry.
    Kirch DG
    Medscape J Med; 2008; 10(8):198. PubMed ID: 18924650
    [No Abstract]   [Full Text] [Related]  

  • 7. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a transparent, actionable framework for public-private partnerships for food and nutrition research.
    Alexander N; Rowe S; Brackett RE; Burton-Freeman B; Hentges EJ; Kretser A; Klurfeld DM; Meyers LD; Mukherjea R; Ohlhorst S
    Am J Clin Nutr; 2015 Jun; 101(6):1359-63. PubMed ID: 26034107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How academic labs can approach the drug discovery process as a way to synergize with big pharma.
    Loregian A; Palù G
    Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting NIH's Integrity and Trustworthiness in Public-Private Partnerships.
    Lo B; Grady D
    JAMA; 2018 Aug; 320(5):439-440. PubMed ID: 30088017
    [No Abstract]   [Full Text] [Related]  

  • 11. Reflections on the Innovative Medicines Initiative.
    Goldman M
    Nat Rev Drug Discov; 2011 May; 10(5):321-2. PubMed ID: 21532547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public-private partnerships at the National Institutes of Health: from discovery to commercialization.
    Lyles A
    Clin Ther; 2003 Nov; 25(11):2900-2. PubMed ID: 14693314
    [No Abstract]   [Full Text] [Related]  

  • 13. Open PHACTS: semantic interoperability for drug discovery.
    Williams AJ; Harland L; Groth P; Pettifer S; Chichester C; Willighagen EL; Evelo CT; Blomberg N; Ecker G; Goble C; Mons B
    Drug Discov Today; 2012 Nov; 17(21-22):1188-98. PubMed ID: 22683805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partnerships between academic psychiatry and the pharmaceutical industry: the Lilly MAP Initiative.
    Singh B; Copolov D; Grainger D; Goh J
    Australas Psychiatry; 2004 Sep; 12(3):220-4; discussion 225-6. PubMed ID: 15715778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing lupus nephritis: algorithms for conservative use of renal biopsy.
    Salach RH; Cash JM
    Cleve Clin J Med; 1996; 63(2):106-15. PubMed ID: 8819695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U-BIOPRED: evaluation of the value of a public-private partnership to industry.
    Riley JH; Erpenbeck VJ; Matthews JG; Holweg CTJ; Compton C; Seibold W; Higenbottam T; Wagers S; Rowe A; Myles D;
    Drug Discov Today; 2018 Sep; 23(9):1622-1634. PubMed ID: 29936248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.
    Zhang Z; Jia M; Wan D
    Int J Health Care Finance Econ; 2009 Jun; 9(2):169-82. PubMed ID: 19360467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public partnerships for a vision for women's health research in 2020.
    Pinn VW; Clayton JA; Begg L; Sass SE
    J Womens Health (Larchmt); 2010 Sep; 19(9):1603-7. PubMed ID: 20815755
    [No Abstract]   [Full Text] [Related]  

  • 20. Building a new biomedical ecosystem: Pfizer's Centers for Therapeutic Innovation.
    Patel AC; Coyle AJ
    Clin Pharmacol Ther; 2013 Sep; 94(3):314-6. PubMed ID: 23645247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.